Results 81 to 90 of about 21,080,479 (286)
, 2023 High response rates in B-cell malignancies have been achieved with chimeric antigen receptor (CAR) T-cell therapy. Emerging reports indicate a risk of active tuberculosis (TB) with novel immunotherapy for tumors.
Liang Huang (114017) +13 more
core +1 more source
Arthritis Care &Research, Accepted Article.Objective Existing patient‐reported outcome (PRO) measures for systemic sclerosis (SSc) have important limitations, including inadequate coverage of early disease and limited inclusion of diffuse cutaneous (dcSSc) and limited cutaneous (lcSSc) subtypes.
George J. Greene +5 more
wiley +1 more source
Cell TransplantationA significant proportion of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) exhibit no response to chimeric antigen receptor (CAR) T-cell therapy or suffer from disease progression thereafter.
Xin Li +6 more
doaj +1 more source
Advanced Functional Materials, EarlyView.Cell therapies typically rely on cold‐chain logistics and cryopreservation, limiting access and compromising cell quality. Here, a dual‐chamber device separates an oxygen‐supplying chamber from a hyaluronic acid cargo chamber, sustaining oxygen delivery for over 70 h and enabling ambient‐temperature shipment.
Daniel A. Domingo‐Lopez +9 more
wiley +1 more source
Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment
Discover OncologyChimeric antigen receptor (CAR)-T-cell therapy is one of the most effective immunotherapies. CAR-T-cell therapy has achieved great success in the treatment of hematological malignancies. However, due to the characteristics of solid malignant tumors, such
Qiuhong Chen, Yang Sun, Hua Li
doaj +1 more source
K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies
Molecular Therapy: OncologyChimeric antigen receptor (CAR)-based therapy is of interest for relapsed or refractory (r/r) T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphomas. A prominent target antigen for this is the receptor CD7, which is expressed in ∼95% of T-ALL, ∼
Nienke Visser +9 more
doaj +1 more source
Chimeric Antigen Receptor T-cell Therapy (CAR T)
, 2022 This is an adoptive T-cell therapy which uses engineered T-cell. In which they are obtain from a patient’s immune system by its own to attack cancer cells through targeting proteins expressed on the cellular membrane, that process involves obtaining T ...
Dr. Vachaspati Narayan, Dr. Mahender Miland, Dr. Kritika Gahlot, Dr. Mukul Purva
core +1 more source
Digitally Printed Eco‐Friendly Electronic Devices
Advanced Functional Materials, EarlyView.Fabrication of electronics using eco‐friendly materials through digital printing routes is a promising strategy for improving life cycle sustainability and reducing the environmental impacts of conventional manufacturing. This review highlights state‐of‐the‐art eco‐friendly materials, green ink formulations, various resource‐efficient digital printing ...
Nitheesh M. Nair +5 more
wiley +1 more source
Modern immunotherapy using CAR-T cells in haemato-oncology and solid tumors [PDF]
CAR-T immunotherapy, based on the genetic modification of T lymphocytes that contain a chimeric antigen receptor (CAR), has been a major breakthrough in the treatment of cancer patients since the 2017 approval of Kymriah™ (tisagenlecleucel) by the United
Olbromski, Krzysztof; Department of Personalized Medicine and Cell Therapy, Regional Blood Center, Poznań, Poland +6 more
core +1 more source
Protease‐Activated Theranostic Nanomedicine for Endometriosis Treatment
Advanced Functional Materials, EarlyView.Endometriosis is a chronic gynecological disorder that affects a substantial proportion of reproductive‐aged women. In this study, we identify aberrant overexpression of matrix metalloproteinase‐9 (MMP‐9) in endometriotic lesions and develop a novel multifunctional nanomedicine that integrates MMP‐9‐targeted therapy, ratiometric photoacoustic (PA ...
Panangattukara Prabhakaran Praveen Kumar +9 more
wiley +1 more source